We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+5.89%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$169M
AUM Growth
-$69.7M
Cap. Flow
-$68M
Cap. Flow %
-40.18%
Top 10 Hldgs %
42.32%
Holding
107
New
38
Increased
7
Reduced
15
Closed
41

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$5.66M
2
EW icon
Edwards Lifesciences
EW
+$3.26M
3
SIEN
Sientra, Inc.
SIEN
+$3.25M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$3M
5
QGEN icon
Qiagen
QGEN
+$2.48M

Top Sells

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$6.09M
2
HCA icon
HCA Healthcare
HCA
+$3.95M
3
BSX icon
Boston Scientific
BSX
+$3.87M
4
HOLX
Hologic
HOLX
+$3.85M
5
ATHN
Athenahealth, Inc.
ATHN
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 51.93%
2 Industrials 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACER
51
DELISTED
Acer Therapeutics Inc
ACER
$805K 0.48%
41,795
-48,865
-54% -$896K
VKTX icon
52
Viking Therapeutics
VKTX
$3.94B
$764K 0.45%
174,870
-259,030
-60% -$1.43M
CLSD
53
DELISTED
Clearside Biomedical
CLSD
$725K 0.43%
+4,507
New +$549K
TGTX icon
54
TG Therapeutics
TGTX
$7.64B
$710K 0.42%
+50,000
New +$639K
STDY
55
DELISTED
SteadyMed Ltd
STDY
$699K 0.41%
215,214
– –
OTIC
56
DELISTED
Otonomy, Inc.
OTIC
$640K 0.38%
152,486
-252,256
-62% -$1.37M
FATE icon
57
Fate Therapeutics
FATE
$319M
$582K 0.34%
+59,600
New +$571K
GWPH
58
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$563K 0.33%
+5,000
New +$629K
CHRS icon
59
CALL
Coherus Oncology
CHRS
$187M
$553K 0.33%
50,000
– –
BHVN
60
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$515K 0.3%
+20,000
New +$598K
JNCE
61
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$485K 0.29%
+21,700
New +$482K
MOTS
62
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$448K 0.26%
+333
New +$469K
ARAY icon
63
Accuray
ARAY
$34.6M
$445K 0.26%
+88,958
New +$466K
KALA icon
64
PUT
KALA BIO
KALA
$16.3M
$237K 0.14%
+6
New +$228K
NTBL
65
PUT
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$230K 0.14%
+2,857
New +$576K
FOMX
66
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$124K 0.07%
24,100
– –
AGEN
67
CALL
Agenus
AGEN
$307M
– –
-3,347
Closed -$214K
ARGX icon
68
argenx
ARGX
$54.1B
– –
-20,400
Closed -$1.29M
AXGN icon
69
Axogen
AXGN
$2.61B
– –
-120,000
Closed -$3.4M
BMY icon
70
PUT
Bristol-Myers Squibb
BMY
$130B
– –
-50,000
Closed -$3.06M
BSX icon
71
PUT
Boston Scientific
BSX
$74.2B
– –
-230,000
Closed -$5.7M
CDTX
72
DELISTED
Cidara Therapeutics
CDTX
– –
-13,750
Closed -$1.87M
CHRS icon
73
Coherus Oncology
CHRS
$187M
– –
-25,000
Closed -$274K
CVS icon
74
CALL
CVS Health
CVS
$120B
– –
-45,000
Closed -$3.26M
DXCM icon
75
PUT
DexCom
DXCM
$33.8B
– –
-227,600
Closed -$3.27M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2018 Portfolio in Review

As of Q1 2018, Pura Vida Investments held 107 positions worth $169M, down 29% from $239M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments withdrew a net $68M in Q1 2018, closing 41 positions and reducing 15 holdings. Its most notable exit was Dentsply Sirona, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 46% a quarter earlier, followed by Industrials.

Against the trend, Pura Vida Investments opened a new position in Merck worth $5.45M.

  • Pura Vida Investments's largest Q1 2018 buy was Merck: 104,800 shares worth $5.45M.
  • Pura Vida Investments added most to Alexion Pharmaceuticals in Q1 2018, an estimated $3M increase.
  • Pura Vida Investments's biggest Q1 2018 reduction was Boston Scientific, cutting an estimated $3.87M.
  • Pura Vida Investments fully exited Dentsply Sirona in Q1 2018, selling an estimated $6.09M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $169M portfolio in Q1 2018.
  • Pura Vida Investments opened 38 new positions and closed 41 in Q1 2018.
  • Pura Vida Investments's portfolio value fell 29% quarter-over-quarter to $169M.

Based on Pura Vida Investments's 13F filing for Q1 2018, filed 14 May 2018.